Background
Methods
Inclusion criteria
Definitions
Statistical analysis
Results
Differences in epidemiological, clinical, and prognostic variables between MRSA versus MSSA IE
MSSA IE N = 378 | MRSA IE N = 59 | p* | |
---|---|---|---|
Mean age (yrs), (± DS) | 58.05. (±17.8) | 62.3. (±15) | 0.048 |
Females, n (%) | 133 (35.2) | 21 (35.6) | 0.95 |
Males | 245 (64.8) | 38 (64.4) | |
Native IE, n (%) | 295 (78) | 44 (74.6) | 0.55 |
Early prosthetic IE, n (%) | 20 (5.3) | 7 (11.9) | 0.07 |
Late prosthetic IE, n (%) | 39 (10.3) | 4 (6.7) | 0.39 |
IE on device (AICD, PMK), n (%) | 34 (8.9) | 5 (8.4) | 0.89 |
Valve involved, n (%) | |||
- Mitral | 209 (55.3) | 31 (52.5) | 0.8 |
- Aortic | 129 (34.1) | 16 (27.1) | 0.34 |
- Mitro-aortic | 17 (4.2) | 4 | 0.5 |
- Mitral, aortic, and tricuspid | 3 (0.8) | 0 | 1 |
- Mitral and tricuspid or Aortic and tricuspid | 16 (4.2) | 1 (1.7) | 0.7 |
- Tricuspid | 46 (12.1) | 7 (11.8) | 0.99 |
- Pulmonary | 4 (1.05) | 1(1.6) | 0.51 |
- IE on interventricular communication, n (%) | 4 (1.05) | 0 | 1 |
Acquisition setting, n (%) | |||
Community | 221(58.5) | 17(28.8) | |
Nosocomial | 128(33.9) | 37(62.7) | 0.0001 |
Healthcare-related | 29(7.7) | 5(8.5) | |
Decade of endocarditis onset, n (%) | |||
1985–1999 | 61 (16.1) | 7(11.8) | 0.4 |
2000–2009 | 136 (35.9) | 20 (33.9) | 0.756 |
2010–2017 | 180 (47.6) | 32 (54.2) | 0.344 |
History of: n (%) | |||
- previous IE | 18 (4.8) | 7(11.9) | 0.64 |
- valve disease on native valve | 171 (45.2) | 24(40.7) | 0.42 |
- Rheumatic | 51 (13.5) | 7(11.9) | 0.68 |
- Myxoid degeneration and/or mitral prolapse | 26 (6.9) | 3 (5.1) | 0.78 |
- Degenerative/calcified | 58 (15.3) | 10 (16.9) | 0.8 |
- Congenital valve disease | 27 (7.1) | 0 | 0.037 |
- Heart disease | 98 (25.9) | 21(35.6) | 0.81 |
- Cardiomyopathy | 35(9.3) | 12(20.4) | 0.01 |
- COPD | 46(12.2) | 18(30.5) | 0.0001 |
- Diabetes Mellitus | 91 (24.1) | 18 (30.5) | 0.22 |
- Peptic ulcer | 5 (1.3) | 3(5.1) | 0.12 |
- Arterial hypertension | 123 (32.5) | 26(44.1) | 0.09 |
- Peripheral vascular disease | 21(5.6) | 6(10.2) | 0.24 |
- Stroke | 21(5.6) | 5(8.5) | 0.37 |
- Dementia | 6(1.6) | 2(3.4) | 0.3 |
- Active neoplasm | 30 (7.9) | 6(10.2) | 0.61 |
- Colonic polyposis | 8 (2.1) | 4 (6.8) | 0.13 |
- Transplant (*) | 5 (1.3) | 0 | 1 |
- Chronic liver disease, n (%) | 49 (12.9) | 6 (10.2) | 0.54 |
- Child-Pugh A | 29 (59.2) | 1(16.7) | |
- Child-Pugh B | 3(6.1) | 1(16.7) | 0.7 |
- Child-Pugh C | 3(6.1) | 1(16.7) | |
- Hemodialysis | 29 (7.7) | 0 | 0.02 |
- Kidney failure | 80 (21.2) | 11(18.6) | 0.6 |
-IVDA | 38(10.1) | 2(3.4) | 0.097 |
Charlson index, median (IQR) | 2(0–3) | 3(1–4) | 0.006 |
Previous invasive procedure or infection focus, n (%) | 216 (57.1) | 47(79.7) | 0.001 |
Vascular | 148 (68.5) | 27(57.4) | 0.63 |
Urinary (catheter) | 7(3.2) | 4(8.5) | 0.08 |
Abdominal | 3(1.4) | 2(4.3) | 0.19 |
Dental | 5(2.3) | 0 | 1 |
Locomotor | 6(2.8) | 3(6.4) | 0.17 |
MSSA IE N = 378 | MRSA IE N = 59 | p* | |
---|---|---|---|
Findings < 1 week before hospitalization, n (%) | 212/355 (59.7) | 22/52 (42.3) | 0.051 |
Clinical n (%) | |||
- Fever | 365(96.6) | 55(93.2) | 0.251 |
- Dyspnea | 174(46) | 31(52.5) | 0.361 |
- Constitutional syndrome | 81(21.4) | 11(18.6) | 0.689 |
- Murmur | 199(52.6) | 30(50.8) | 0.822 |
- Hepatomegaly | 66(17.4) | 8(13.6) | 0.420 |
- Splenomegaly | 48(12.7) | 9(15.3) | 0.615 |
- CNS | 156(41.3) | 18(30.5) | 0.116 |
Encephalopathy | 76 (20.1) | 9 (15.3) | 0.4 |
Meningitis | 20 (5.3) | 1 (1.69) | 0.3 |
Abscess | 6 (1.6) | 0 | 1 |
Embolic non-hemorrhagic stroke | 62 (16.4) | 7 (11.9) | 0.43 |
Embolic hemorrhagic stroke | 11 (2.9) | 2 (3.39) | 0.68 |
Hemorrhagic stroke with no previous Embolism | 22 (5.8) | 2 (3.39) | 0.75 |
- Renal embolism | 6(1.6) | 0 | 1 |
- Spleen embolism | 22(5.8) | 5(8.5) | 0.387 |
- Large vessel embolism | 30(7.9) | 5(8.5) | 0.799 |
- Pulmonary embolism | 27(7.1) | 8(13.6) | 0.119 |
- Roth’s spots | 13 (3.4) | 0 | 0.228 |
- Conjunctival hemorrhage | 15(3.9) | 0 | 0.230 |
- Endophthalmitis | 0 | 1 (1.7) | 0.127 |
- Cutaneous manifestation | 108 (28.6) | 11 (18.6) | 0.093 |
- Petechiae | 80 (21.2) | 7 (11.9) | 0.115 |
- Janeway lesions | 53(14) | 3(5.1) | 0.054 |
- Osler’s nodes | 61(16.1) | 4(6.8) | 0.057 |
- Splinter hemorrhage | 43(11.4) | 5(8.5) | 0.496 |
- Duke vascular or embolic phenomena | 120(31.7) | 12(20.4) | 0.072 |
- Duke immunological phenomena | 29 (7.7) | 1 (1.7) | 0.099 |
- Osteoarticular involvement | 52(13.8) | 8(13.6) | 0.98 |
- Acute kidney failure during hospitalization | 159(42) | 22(37.3) | 0.469 |
- Heart failure | 171 (45.2) | 25(42.4) | 0.643 |
Grade III-IV | 90 (23.8) | 18 (30.5) | 0.3 |
- Severe sepsis/Septic shock | 97(25.7) | 14(23.7) | 0.751 |
- Acute pulmonary edema | 93(24.6) | 17(28.8) | 0.446 |
Echocardiographic findings, n (%) ** | |||
- Diagnostic data | 336 (88.9) | 49(83.1) | 0.34 |
- Vegetation | 249(65.9) | 43 (72.9) | 0.615 |
- Perivalvular lesion | 107(28.3) | 9(15.3) | 0.043 |
- Pseudoaneurysm | 14(3.7) | 1(1.7) | 0.7 |
- Fistula in valvular system | 8(2.1) | 2(3.4) | 0.63 |
- Valvular system rupture or perforation | 63(16.7) | 6(10.2) | 0.226 |
- Prosthesis dehiscence or dysfunction | 23(6.1) | 5(8.5) | 0.39 |
- Pericardial effusion | 14(3.7) | 2(4.4) | 1 |
IE classification, n(%) | |||
Possible | 25 (6.6) | 7(11.9) | |
Definite | 352(93.1) | 52(88.1) | 0.18 |
MSSA IE N = 378 | MRSA IE N = 59 | p* | |
---|---|---|---|
Mortality at 1 year, n (%) | 165 (43.7) | 29 (49.1) | 0.32 |
Mortality at 1 year not related to IE, n (%) | 13 (4.2) | 0 | 0.316 |
Mortality attributable to SA IE in hospital or during the first 30 days post-discharge, n (%) | 152 (40.2) | 29 (49.1) | 0.222 |
Mortality attributable to IE in the following periods, n (%) | |||
1984–1999 | 35 (23) | 2 (6.99) | 0.122 |
2000–2009 | 64 (42.1) | 12 (41.4) | 0.215 |
2010–2017 | 52 (34.2) | 15 (51.7) | 0.062 |
Reinfection, n (%) | 6 (1.5) | 0 | 0.316 |
IE relapse, n (%) | 8 (3.1) | 4(6.8) | 0.053 |
Adequacy of antibiotic therapy, n (%) | 302/332 (91) | 40/46 (87) | 0.085 |
Days of antibiotic therapy, median (IQR) | 32 (19–44.5) | 41 (20–62) | 0.219 |
Hospital stay (days), median (IQR) | 30 (16–47) | 37 (21–58) | 0.019 |
Surgery not indicated n (%) | 128 (33.9) | 18 (30.5) | 0.189 |
Surgical treatment on admission, n (%) | 127 (32) | 15 (25.4) | 0.13 |
Postponed surgery after discharge, n (%) | 8 (2.1) | 0 | 0.61 |
Surgery indicated and conducted without delay, n (%) | 117 (30.9) | 12 (20.3) | 0.11 |
Surgery indicated and conducted with delay: > 72 h in left ventricular failure grade IV, n (%) | 9 (2.4) | 3 (5.1) | 0.21 |
Surgery indicated and not conducted in hospital, n (%) | 88 (23.3) | 18 (30.5) | 0.23 |
Surgery indicated but not conducted, n (%) | 38 (10.1) | 11 (18.6) | 0.052 |
Surgery indicated but not conducted due to poor clinical status, n (%) | 50 (13.2) | 7 (11.86) | 0.7 |
OR | 95% CI | |
---|---|---|
COPD | 3.19 | 1.4–7.23 |
Early prosthetic IE | 2.13 | 0.69–3.98 |
Nosocomial or healthcare-related IE | 1.64 | 0.69–3.99 |
Cardiomyopathy | 2.22 | 0.84–5.91 |
Congenital disease | 0 | 0 |
Arterial hypertension | 1.16 | 0.54–2.49 |
Hemodialysis | 0 | 0 |
Charlson’s index | 0.92 | 0.776–1.095 |
Invasive procedure and/or focus of infection | 2.95 | 1.14–7.65 |
IVDA | 1.18 | 0.21–6.66 |
Osler’s node | 0.73 | 0.163–3.24 |
Janeway lesion | 0.737 | 0.137–3.96 |
Duke vascular or embolic phenomena | 0.19 | 0.716–5.493 |
Delay in hospital care | 3.94 | 1.64–9.468 |
Echocardiography with perivalvular lesion | 0.395 | 0.15–1.03 |
Adequate antibiotic therapy | 0.532 | 0.214–1.321 |
Prognostic value for IE of vancomycin MIC> 1 μg/mL for MRSA
Risk factors associated with mortality from SA
Death N = 182 | Survivors N = 224 | p* | OR (95% CI); p* | |
---|---|---|---|---|
Age (yrs), media (± DS) | 61.5 (±16.83) | 56.4 (±17.75) | 0.004 | 1.02(0.997–1.042); 0.09 |
Females, n (%) | 66 (36.3) | 76 (33.9) | 0.62 | |
Native IE, n (%) | 146(80.2) | 168(75) | 0.21 | |
Early prosthetic IE, n (%) | 17(9.4) | 9 (4) | 0.028 | 1.307(0.395–4.328); 0.661 |
Late prosthetic IE, n (%) | 22 (12.2) | 20(8.9) | 0.29 | |
IE in devices (AICD, PMK), n (%) | 5 (2.8) | 29(12.9) | 0.0001 | 0.34(0.06–2.12); 0.252 |
Affected valve, n (%) | ||||
Mitral | 115 (64.6) | 110 (49.5) | 0.03 | 1.456 (0.742–2.86); 0.274 |
Aortic | 61 (34.1) | 73 (32.9) | 0.83 | |
Tricuspid | 21 (11.7) | 30 (13.5) | 0.59 | |
Pulmonary | 4 (2.2) | 0 | 0.025 | |
Mitral and aortic | 9 (4.9) | 12 (5.3) | 0.91 | |
Mitral, aortic, and tricuspid | 2 (1.1) | 1(0.04) | 0.59 | |
Mitral and tricuspid | 10 (5.5) | 6 (2.6) | 0.19 | |
Community acquisition setting, n (%) | 93 (51.1) | 129 (57.6) | 0.181 | |
Decade of endocarditis onset, n (%) | ||||
1985–1999 | 37 (20.3) | 28 (12.5) | 0.0032 | 8.391(2.82–24.95); 0.0001 |
2000–2009 | 78 (42.9) | 67(29.9) | 0.007 | 6.41 (2.921–14.06); 0.0001 |
2010–2017 | 67 (36.8) | 129 (57.6) | 0.0001 | |
Hospital where IE was treated, n (%) | ||||
HUVR, (n = 156) | 75 (41.2) | 81 (36.2) | ||
HUVM, (n = 47) | 18 (9.9) | 29 (12.9) | ||
HURM, (n = 63) | 28 (15.4) | 35 (15.6) | ||
HUVV, (n = 54) | 24 (13.2) | 30 (11.4) | 0.189 | |
HCS, (n = 18) | 8 (4.4) | 10 (4.5) | ||
HJRJ, (n = 23) | 15 (8.2) | 8 (3.6) | ||
HUSC, (n = 11) | 5 (2.7) | 6 (2.7) | ||
HUVN, (n = 34) | 9 (4.9) | 25 (11.2) | ||
History of, n (%): | ||||
- Previous IE | 11 (4.9) | 12(36.6) | 0.473 | |
- Previous valve disease | 90 (51.7) | 92(42.2) | 0.060 | 0.846(0.437–1.64);0.621 |
Rheumatic | 33 (19.4) | 22(10.2) | 0.011 | |
Myxoid | 8 (4.7) | 20(9.3) | 0.085 | |
Degenerative/calcified | 36 (21.2) | 27(12.6) | 0.023 | |
Congenital | 6 (3.5) | 16(7.4) | 0.101 | |
- Heart disease | 110 (60.4) | 123(54.9) | 0.288 | |
- Acute myocardial infarction previous to IE | 8 (4.4) | 12(5.4) | 0.674 | |
- Auricular fibrillation | 20(11.1) | 17(7.6) | 0.223 | |
- Cardiomyopathy | 17 (9.4) | 26(11.6) | 0.484 | |
- COPD | 31(17.2) | 27(12.1) | 0.141 | |
- Diabetes mellitus | 49(27.2) | 52(23.2) | 0.355 | |
- Hypertension | 56(30.8) | 84(37.7) | 0.146 | |
- Peripheral vascular disease | 9(5) | 16(7.1) | 0.336 | |
- Stroke | 14(7.8) | 12(5.4) | 0.149 | |
- Dementia | 5(2.8) | 2(0.9) | 0.25 | |
- Active neoplasm | 20(11.2) | 13 (5.8) | 0.051 | 6.627(1.72–25.53); 0.006 |
- Kidney failure | 38 (21) | 47(21) | 0.998 | |
- Hemodialysis | 12(6.6) | 16 (7) | 0.86 | |
- Liver disease | 22 (12.2) | 29 (12.9) | 0.811 | |
- Child-Pugh A | 10 () | 18 () | ||
- Child-Pugh B | 5() | 4 () | 0.553 | |
- Child-Pugh C | 2 (1.1) | 2 (0.9) | ||
- HIV infection | 4(2.2) | 7(3.2) | 0.76 | |
- IVDA | 15(8.3) | 23(10.3) | 0.508 | |
-Transplant (*) | 0 | 5(2.2) | 0.068 | |
Charlson’s index, median (IQR) | 4 (2–5) | 2 (0.9–4) | 0.084 | |
History of invasive procedure or previous focus, n (%) | 115 (63.2) | 133 (59.6) | 0.46 | |
Going to hospital during first 7 days of symptom onset, n (%) | 110 (63.6) | 105(51.5) | 0.018 | |
Adequate antibiotic treatment, n (%) | 139(76.4) | 183 (81.6 | 0.362 | |
Severe sepsis/septic shock, n (%) | 85(46.7) | 62(27.8) | 0.0001 | 2.286(1.053–4.96); 0.037 |
Manifestations in CNS, n (%) | 93 (51.1) | 73 (32.6) | 0.0001 | 0.878(0.433–1.778); 0.717 |
- Encephalopathy | 47 (37.6) | 35 (22.6) | 0.006 | |
- Meningitis | 11 (8.9) | 9 (5.8) | 0.035 | |
- Brain abscess | 0 | 6 (3.9) | 0.027 | |
- Embolic stroke | 37 (29.6) | 29 (18.7) | 0.033 | |
- Hemorrhagic stroke with no previous embolism | 14 (11.3) | 8 (5.2) | 0.059 | |
Renal embolism, n (%) | 5 (2.8) | 1 (0.4) | 0.092 | |
Large vessel embolism, n (%) | 13 (7.3) | 18 (8.1) | 0.775 | |
Spleen embolism, n (%) | 11(6.2) | 16 (7.2) | 0.693 | |
Kidney failure during IE (**), n (%) | 94 (52.2) | 6 (33.9) | 0.0001 | 1.279 (0.67–2.44); 0.455 |
Heart failure, n (%) | 109 (60.2) | 75 (33.8) | 0.0001 | 1.65(0.773–3.523); 0.196 0.846(0.312- |
Osteoarticular dissemination, n (%) | 17 (9.6) | 38 (17.3) | 0.026 | 2.295); 0.743 |
MRSA, n (%) | 30 (16.5) | 27 (12.1) | 0.201 | |
Surgery performed, n (%) | 50(27.5) | 82(36.6) | 0.051 | 1.778 (0.299–10.592); 0.527 |
Surgery indicated and conducted without delay, n (%) | 42(23.1) | 81 (36.2) | 0.004 | 0.242(0.041–1.426); 0.117 |
Surgery indicated and conducted with delay > 48 h in left ventricular failure, n (%) | 9 (4.9) | 2(0.89) | 0.015 | |
Surgery indicated and not conducted, n (%) | 30(16.5) | 11(4.9) | 0.0001 | 2.866(0.936–7.707); 0.066 |
Early surgery < 2 weeks, n(%) | 24 (48) | 47 (57.3) | 0.68 | |
EuroSCORE, median (IQR) | 13 (9.5–16) | 9(7–12) | 0.0001 | 1.038(0.862–1.25); 0.692 |
Logistic EuroSCORE, median (IQR) | 30.76(14.7–58.7) | 15.4(8.05–28.1) | 0.0001 | 1.033(0.997–1.069);0.07 |
Relapse, n (%) | 5 (2.7) | 9 (4) | 0.480 | |
Reinfection, n (%) | 0 | 6 (2.6) | 1 |